Description: Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new molecular entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Track Therapeutic’s executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products that achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases.
Home Page: www.frtx.com
FRTX Technical Analysis
5777 Central Avenue
Boulder,
CO
80301
United States
Phone:
720 505 4755
Officers
| Name | Title |
|---|---|
| Mr. Reginald L. Hardy M.B.A., R.Ph. | Co-Founder & Chairman |
| Attorney Robert Busard Brown | CEO & Director |
| Mr. Andrew D. Sklawer | Co-Founder, Pres & Sec. |
| Mr. Deepak Chadha M.B.A., M.S., MBA, MS, RAC | Chief R&D Officer and COO |
| Mr. Albert Nicholas Marchio II | CFO and Principal Accounting & Financial Officer |
| Mr. David R. Mcavoy J.D. | Gen. Counsel & Chief Compliance Officer |
| Mr. Gary S. Walker | Chief Marketing Officer |
| Aron Aizenstat M.B.A., P.M.P. | VP of Corp. Devel. & Operations |
| Ms. Sue Fattor | Head of Human Resource |
| Ms. Nancy Seretta | VP & Head of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.392 |
| Price-to-Sales TTM: | 0.8623 |
| IPO Date: | 2022-09-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |